BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22865295)

  • 1. Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients.
    Roelofsen T; Mingels M; Hendriks JC; Samlal RA; Snijders MP; Aalders AL; Bulten J; van Ham MA; Massuger LF
    Int J Biol Markers; 2012 Oct; 27(3):e263-71. PubMed ID: 22865295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma.
    Olawaiye AB; Rauh-Hain JA; Withiam-Leitch M; Rueda B; Goodman A; del Carmen MG
    Gynecol Oncol; 2008 Sep; 110(3):293-8. PubMed ID: 18644620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma.
    Schmidt M; Segev Y; Sadeh R; Suzan E; Feferkorn I; Kaldawy A; Kligun G; Lavie O
    Int J Gynecol Cancer; 2018 Sep; 28(7):1311-1317. PubMed ID: 29958235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma.
    Gupta D; Gunter MJ; Yang K; Lee S; Zuckerwise L; Chen LM; Goldberg GL; Huang GS
    Int J Gynecol Cancer; 2011 Apr; 21(3):529-34. PubMed ID: 21436701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer.
    Frimer M; Hou JY; McAndrew TC; Goldberg GL; Shahabi S
    Reprod Sci; 2013 Apr; 20(4):449-55. PubMed ID: 22995987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of serum CA-125 in predicting extra-uterine disease in apparent early-stage endometrial cancer.
    Nicklin J; Janda M; Gebski V; Jobling T; Land R; Manolitsas T; McCartney A; Nascimento M; Perrin L; Baker JF; Obermair A;
    Int J Cancer; 2012 Aug; 131(4):885-90. PubMed ID: 21918977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a preoperative predictive factor for lymph node metastasis in uterine papillary serous carcinoma: long-term results from a single institution.
    Baek MH; Lee SW; Park JY; Kim D; Kim JH; Kim YM; Kim YT; Nam JH
    Int J Gynecol Cancer; 2015 Jan; 25(1):69-74. PubMed ID: 25470688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.
    Huang CY; Tang YH; Chiang YC; Wang KL; Fu HC; Ke YM; Lau HY; Hsu KF; Wu CH; Cheng WF
    Gynecol Oncol; 2014 May; 133(2):221-8. PubMed ID: 24556064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study.
    Mahdi H; Elshaikh MA; DeBenardo R; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; Moslemi-Kebria M
    Gynecol Oncol; 2015 May; 137(2):239-44. PubMed ID: 25641568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease.
    Bristow RE; Asrari F; Trimble EL; Montz FJ
    Gynecol Oncol; 2001 May; 81(2):279-86. PubMed ID: 11330963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine papillary serous cancer: a review of the literature.
    del Carmen MG; Birrer M; Schorge JO
    Gynecol Oncol; 2012 Dec; 127(3):651-61. PubMed ID: 23000148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of thrombocytosis in uterine papillary serous carcinomas.
    Lerner DL; Walsh CS; Cass I; Karlan BY; Li AJ
    Gynecol Oncol; 2007 Jan; 104(1):91-4. PubMed ID: 16934317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
    Fader AN; Starks D; Gehrig PA; Secord AA; Frasure HE; O'Malley DM; Tuller ER; Rose PG; Havrilesky LJ; Moore KN; Huh WK; Axtell AE; Kelley JL; Zanotti KM;
    Gynecol Oncol; 2009 Nov; 115(2):244-8. PubMed ID: 19712966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uterine papillary serous carcinoma pre-operatively diagnosed as endometrioid carcinoma: Is omentectomy necessary?
    Peled Y; Aviram A; Krissi H; Gershoni A; Sabah G; Levavi H; Eitan R
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):498-502. PubMed ID: 26235227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.
    Rauh-Hain JA; Growdon WB; Schorge JO; Goodman AK; Boruta DM; McCann C; Horowitz NS; del Carmen MG
    Gynecol Oncol; 2010 Nov; 119(2):299-304. PubMed ID: 20691465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased expression of 14-3-3σ is predictive of poor prognosis for patients with human uterine papillary serous carcinoma.
    Suzuki F; Nagase S; Suzuki K; Oba E; Hiroki E; Matsuda Y; Akahira J; Nishigori H; Sugiyama T; Otsuki T; Yoshinaga K; Takano T; Niikura H; Ito K; Sasano H; Yaegashi N
    Tohoku J Exp Med; 2013 Nov; 231(3):193-9. PubMed ID: 24201220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma.
    Abramovich D; Markman M; Kennedy A; Webster K; Belinson J
    J Cancer Res Clin Oncol; 1999 Dec; 125(12):697-8. PubMed ID: 10592103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen.
    Lee LJ; Demaria R; Berkowitz R; Matulonis U; Viswanathan AN
    Gynecol Oncol; 2014 Jan; 132(1):65-9. PubMed ID: 24211401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
    BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.